NetraMark Announces Private Placement Financing

Core Viewpoint - NetraMark Holdings Inc. is conducting a non-brokered private placement to raise up to $3,500,000 CDN through the issuance of 3,500,000 units at a price of $1.00 per unit, aimed at advancing its AI-powered clinical trial analytics platform and supporting biopharmaceutical engagements [1][4]. Group 1: Offering Details - The offering consists of units that include one common share and one-half of a common share purchase warrant, with the whole warrant allowing the purchase of an additional share at $1.35 for two years [2]. - The offering will be completed under exemptions from prospectus requirements, with a statutory hold period of four months and one day for the issued shares and warrants [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general working capital and corporate purposes, specifically for the advancement and commercialization of the NetraAI platform and support for ongoing and prospective biopharmaceutical engagements [4]. Group 3: Company Overview - NetraMark focuses on developing Generative AI and Machine Learning solutions for the pharmaceutical industry, utilizing a unique topology-based algorithm to analyze patient data effectively [7]. - The NetraAI platform is designed to separate small datasets into explainable and unexplainable subsets, enhancing the accuracy of clinical trial insights and reducing the risk of overfitting [6].